{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:06:12Z","timestamp":1790697972610,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p><jats:sup>177<\/jats:sup>Lu-Dotatate is an emerging treatment modality for patients with unresectable or metastatic well-differentiated NETs. This study examines survival predictors in patients who received <jats:sup>177<\/jats:sup>Lu-Dotatate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective single-center review was conducted, examining 47 individuals with progressive well-differentiated NETs treated with <jats:sup>177<\/jats:sup>Lu-Dotatate (four induction cycles of 5.5\u00a0GBq at 10-week intervals followed by eight maintenance cycles of 3.7\u00a0GBq at 6-month intervals).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Median follow-up was 63.1\u00a0months with a median progression-free survival (PFS) of 34.1\u00a0months. However, median overall survival (OS) was not reached at the time of analysis. The presence of \u2265\u20095 bone metastases (hazard ratio HR 4.33; <jats:italic>p<\/jats:italic>\u2009=\u20090.015), non-gastroenteropancreatic (non-GEP) NETs (HR 3.22; <jats:italic>p<\/jats:italic>\u2009=\u20090.025) and development of interim ascites (HR 3.15; <jats:italic>p<\/jats:italic>\u2009=\u20090.047) independently predicted a worse OS. Patients with chromogranin A of \u2265\u20094\u2009\u00d7\u2009upper limit of normal (ULN) had shorter OS (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and PFS (<jats:italic>p<\/jats:italic>\u2009=\u20090.004). Similarly, those with pre-existing ascites demonstrated a worse OS (<jats:italic>p<\/jats:italic>\u2009=\u20090.009) and PFS (<jats:italic>p<\/jats:italic>\u2009=\u20090.026). Liver metastases involving greater than 50% liver volume and the existence of unusual metastatic locations had a negative impact on OS (<jats:italic>p<\/jats:italic>\u2009=\u20090.033) and PFS (<jats:italic>p<\/jats:italic>\u2009=\u20090.026), respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>High burden of skeletal and hepatic metastases, non-GEP-NETs, chromogranin A of\u2009\u2265\u20094\u2009\u00d7\u2009ULN, unusual metastatic sites, pre-existing and interim ascites are predictors of poor outcomes in patients treated with <jats:sup>177<\/jats:sup>Lu-Dotatate. These common indicators can be used for the risk stratification and identification of patients most likely to benefit from PRRT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov identifier: NCT02236910, Retrospectively registered on September, 2014.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-021-03672-w","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T07:07:21Z","timestamp":1623308841000},"page":"225-236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)"],"prefix":"10.1007","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3405-7497","authenticated-orcid":false,"given":"Mina M.","family":"Swiha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan E. K.","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6525-5157","authenticated-orcid":false,"given":"Golmehr","family":"Sistani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6320-7565","authenticated-orcid":false,"given":"Alireza","family":"Khatami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8504-1930","authenticated-orcid":false,"given":"Rami M.","family":"Abazid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol","family":"Mujoomdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele P.","family":"Wiseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan G.","family":"Romsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Laidley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"issue":"13","key":"3672_CR1","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3748\/wjg.v26.i13.1513","volume":"26","author":"E Abou Jokh Casas","year":"2020","unstructured":"Abou Jokh Casas E, Pubul N\u00fa\u00f1ez V, Anido-Herranz U et al (2020) Evaluation of 177Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors. World J Gastroenterol 26(13):1513\u20131524. https:\/\/doi.org\/10.3748\/wjg.v26.i13.1513","journal-title":"World J Gastroenterol"},{"issue":"9","key":"3672_CR2","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1080\/00365520903082432","volume":"44","author":"DS Bergestuen","year":"2009","unstructured":"Bergestuen DS, Aabakken L, Holm K et al (2009) Small intestinal neuroendocrine tumors: prognostic factors and survival. Scand J Gastroenterol 44(9):1084\u20131091. https:\/\/doi.org\/10.1080\/00365520903082432","journal-title":"Scand J Gastroenterol"},{"issue":"9","key":"3672_CR3","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1016\/S1470-2045(20)30323-5","volume":"21","author":"L Bodei","year":"2020","unstructured":"Bodei L, Sch\u00f6der H, Baum RP et al (2020) Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. Lancet Oncol 21(9):e431\u2013e443. https:\/\/doi.org\/10.1016\/S1470-2045(20)30323-5","journal-title":"Lancet Oncol"},{"issue":"3","key":"3672_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1530\/ERC-15-0490","volume":"23","author":"ME Caplin","year":"2016","unstructured":"Caplin ME, Pavel M, \u0106wik\u0142a JB et al (2016) Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer 23(3):191\u2013199. https:\/\/doi.org\/10.1530\/ERC-15-0490","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"3672_CR5","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D et al (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3(10):1335\u20131342. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589","journal-title":"JAMA Oncol"},{"issue":"2","key":"3672_CR6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2967\/jnumed.113.125336","volume":"55","author":"S Ezziddin","year":"2014","unstructured":"Ezziddin S, Attassi M, Yong-Hing CJ et al (2014) Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med 55(2):183\u2013190. https:\/\/doi.org\/10.2967\/jnumed.113.125336","journal-title":"J Nucl Med"},{"issue":"6","key":"3672_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1477-2574.2010.00175.x","volume":"12","author":"A Frilling","year":"2010","unstructured":"Frilling A, Sotiropoulos GC, Li J et al (2010) Multimodal management of neuroendocrine liver metastases. HPB (oxford) 12(6):361\u2013379. https:\/\/doi.org\/10.1111\/j.1477-2574.2010.00175.x","journal-title":"HPB (oxford)"},{"key":"3672_CR8","doi-asserted-by":"publisher","first-page":"175883592094237","DOI":"10.1177\/1758835920942378","volume":"12","author":"A Galvano","year":"2020","unstructured":"Galvano A, Peri M, Guarini AA et al (2020) Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score. Ther Adv Med Oncol 12:1758835920942378. https:\/\/doi.org\/10.1177\/1758835920942378","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"3672_CR9","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1093\/annonc\/mdq022","volume":"21","author":"R Garcia-Carbonero","year":"2010","unstructured":"Garcia-Carbonero R, Capdevila J, Crespo-Herrero G et al (2010) Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 21(9):1794\u20131803. https:\/\/doi.org\/10.1093\/annonc\/mdq022","journal-title":"Ann Oncol"},{"issue":"2","key":"3672_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/MPA.0000000000000267","volume":"44","author":"J Kavecansky","year":"2015","unstructured":"Kavecansky J, Wei L, Caronia L et al (2015) Bone metastases in well-to-moderately differentiated neuroendocrine tumors: a single institutional review from the Ohio State University Medical Center. Pancreas 44(2):198\u2013203. https:\/\/doi.org\/10.1097\/MPA.0000000000000267","journal-title":"Pancreas"},{"issue":"Suppl 1","key":"3672_CR11","first-page":"62S","volume":"46","author":"DJ Kwekkeboom","year":"2005","unstructured":"Kwekkeboom DJ, Mueller-Brand J, Paganelli G et al (2005) Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46(Suppl 1):62S-S66","journal-title":"J Nucl Med"},{"issue":"3","key":"3672_CR12","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1159\/000493317","volume":"107","author":"FM Laskaratos","year":"2018","unstructured":"Laskaratos FM, Walker M, Wilkins D et al (2018) Evaluation of clinical prognostic factors and further delineation of the effect of mesenteric fibrosis on survival in advanced midgut neuroendocrine tumours. Neuroendocrinology 107(3):292\u2013304. https:\/\/doi.org\/10.1159\/000493317","journal-title":"Neuroendocrinology"},{"key":"3672_CR13","unstructured":"Millburn N (2018) Lutetium 177Lu-Dotatate (insert package). In: advanced accelerator applications USA, Inc. U.S. National library of medicine. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=72d1a024-00b7-418a-b36e-b2cb48f2ab55. Accessed 09 Aug 2018"},{"issue":"1","key":"3672_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5694\/j.1326-5377.2010.tb03742.x","volume":"193","author":"IM Modlin","year":"2010","unstructured":"Modlin IM, Moss SF, Oberg K et al (2010) Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. Med J Aust 193(1):46\u201352. https:\/\/doi.org\/10.5694\/j.1326-5377.2010.tb03742.x","journal-title":"Med J Aust"},{"issue":"6","key":"3672_CR15","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1097\/RLU.0b013e318252d2c3","volume":"38","author":"N Naswa","year":"2013","unstructured":"Naswa N, Sharma P, Kumar R et al (2013) Usual and unusual neuroendocrine tumor metastases on (68)Ga-DOTANOC PET\/CT: a pictorial review. Clin Nucl Med 38(6):e239\u2013e245. https:\/\/doi.org\/10.1097\/RLU.0b013e318252d2c3","journal-title":"Clin Nucl Med"},{"issue":"12","key":"3672_CR16","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","volume":"19","author":"B Oronsky","year":"2017","unstructured":"Oronsky B, Ma PC, Morgensztern D et al (2017) Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia 19(12):991\u20131002. https:\/\/doi.org\/10.1016\/j.neo.2017.09.002","journal-title":"Neoplasia"},{"issue":"1","key":"3672_CR17","first-page":"25","volume":"44","author":"JL Pasieka","year":"2001","unstructured":"Pasieka JL, McKinnon JG, Kinnear S et al (2001) Carcinoid syndrome symposium on treatment modalities for gastrointestinal carcinoid tumours: symposium summary. Can J Surg 44(1):25\u201332","journal-title":"Can J Surg"},{"issue":"7","key":"3672_CR18","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3109\/0284186X.2015.1043026","volume":"54","author":"F Petrelli","year":"2015","unstructured":"Petrelli F, Cabiddu M, Coinu A et al (2015) Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol 54(7):961\u2013970. https:\/\/doi.org\/10.3109\/0284186X.2015.1043026","journal-title":"Acta Oncol"},{"issue":"28","key":"3672_CR19","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, M\u00fcller HH, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27(28):4656\u20134663. https:\/\/doi.org\/10.1200\/JCO.2009.22.8510","journal-title":"J Clin Oncol"},{"issue":"6","key":"3672_CR20","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1200\/JCO.2015.64.0987","volume":"34","author":"SM Sadowski","year":"2016","unstructured":"Sadowski SM, Neychev V, Millo C et al (2016) Prospective study of 68Ga-DOTATATE positron emission tomography\/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol 34(6):588\u2013596. https:\/\/doi.org\/10.1200\/JCO.2015.64.0987","journal-title":"J Clin Oncol"},{"issue":"1","key":"3672_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3390\/curroncol28010015","volume":"28","author":"G Sistani","year":"2020","unstructured":"Sistani G, Sutherland DEK, Mujoomdar A et al (2020) Efficacy of 177Lu-Dotatate induction and maintenance therapy of various types of neuroendocrine tumors: a phase ii registry study. Curr Oncol 28(1):115\u2013127. https:\/\/doi.org\/10.3390\/curroncol28010015","journal-title":"Curr Oncol"},{"issue":"1","key":"3672_CR22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12885-020-07710-7","volume":"21","author":"J Smith-Palmer","year":"2021","unstructured":"Smith-Palmer J, Leeuwenkamp OR, Virk J et al (2021) Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland. BMC Cancer 21(1):10. https:\/\/doi.org\/10.1186\/s12885-020-07710-7","journal-title":"BMC Cancer"},{"issue":"1","key":"3672_CR23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/annonc\/mds276","volume":"24","author":"H Sorbye","year":"2013","unstructured":"Sorbye H, Welin S, Langer SW et al (2013) Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 24(1):152\u2013160. https:\/\/doi.org\/10.1093\/annonc\/mds276","journal-title":"Ann Oncol"},{"issue":"15","key":"3672_CR24","doi-asserted-by":"publisher","first-page":"e15683","DOI":"10.1200\/jco.2009.27.15_suppl.e15683","volume":"27","author":"R Srirajaskanthan","year":"2009","unstructured":"Srirajaskanthan R, Desai K, Jayaratnam A et al (2009) Uncommon sites for metastasis of neuroendocrine tumor in adults. J Clin Oncol 27(15):e15683\u2013e15683","journal-title":"J Clin Oncol"},{"issue":"2","key":"3672_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E et al (2017) Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med 376(2):125\u2013135. https:\/\/doi.org\/10.1056\/NEJMoa1607427","journal-title":"N Engl J Med"},{"issue":"3","key":"3672_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u2013216. https:\/\/doi.org\/10.1093\/jnci\/92.3.205","journal-title":"J Natl Cancer Inst"},{"issue":"1091","key":"3672_CR27","doi-asserted-by":"publisher","first-page":"20180041","DOI":"10.1259\/bjr.20180041","volume":"91","author":"E Vaughan","year":"2018","unstructured":"Vaughan E, Machta J, Walker M et al (2018) Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response. Br J Radiol 91(1091):20180041. https:\/\/doi.org\/10.1259\/bjr.20180041","journal-title":"Br J Radiol"},{"issue":"4","key":"3672_CR28","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1097\/MPA.0b013e3182156c0b","volume":"40","author":"RR Warner","year":"2011","unstructured":"Warner RR, Curran T, Shafir MK et al (2011) Serum and ascites chromogranin-A in patients with metastatic neuroendocrine tumors. Pancreas 40(4):622\u2013626. https:\/\/doi.org\/10.1097\/MPA.0b013e3182156c0b","journal-title":"Pancreas"},{"issue":"18","key":"3672_CR29","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A et al (2008) One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063\u20133072. https:\/\/doi.org\/10.1200\/JCO.2007.15.4377","journal-title":"J Clin Oncol"},{"issue":"12","key":"3672_CR30","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1210\/jc.2011-0666","volume":"96","author":"JC Yao","year":"2011","unstructured":"Yao JC, Pavel M, Phan AT et al (2011) Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab 96(12):3741\u20133749. https:\/\/doi.org\/10.1210\/jc.2011-0666","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03672-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03672-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03672-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T13:05:35Z","timestamp":1641906335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03672-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["3672"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03672-w","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,10]]},"assertion":[{"value":"8 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee at Lawson Health Research Institute (Ethics no: 104378).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All the patients signed informed written consent before participation in the trial.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}